European Commission logo
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-05-18

European study of clinical, health economic and quality of life outcomes in Haemophilia treatment

Objective

This study has been designed to evaluate the quality of haemophilia care in Europe to describe the Sol of European haemophiliacs and to estimate the costs needed to attain these levels of quality of life. About 2040 Patients will be recruited con-seductively from haemophilia comprehensive care centres from 22 Countries. The Study will consist of a Sol Study, Cost-of-Illness-, Cost-Effectiveness- and Cost-Utility-Analysis to perform total costs due to haemophilia, to compare alternative treatments and to determine patient's preferences. Haemophiliac patients from 4 years on will be stratified according to following characteristics: severity of haemophilia, presence of inhibitors, treatment schemes. Clinical and health economic data will be assessed at baseline and prospectively over a 6-month follow-up period. In addition the patients fill in a diary during the follow-up period.

Call for proposal

Data not available

Coordinator

LUDWIG-MAXIMILIANS UNIVERSITY OF MUNICH
EU contribution
No data
Address
Geschwister-Scholl-Platz 1
80539 MUENCHEN
Germany

See on map

Total cost
No data

Participants (7)